How Artificial Intelligence is Changing Biotech & Drug Discovery

AI is already making parts of biotech and drug discovery more efficient, but the guest argues it has not yet solved the hardest problem: improving biology. The clearest gains are earlier in the pipeline, where AI can help design molecules faster and shorten the time from idea to a development candidate, with some companies reportedly reaching that stage in about 17 months.

The guest says AI has also improved productivity in moving from phase one to phase two and may be lifting success rates there, but the phase two to phase three transition has not improved. That matters because phase two is where companies get the first real proof that a drug is changing disease outcomes, so faster molecule design does not automatically translate into better clinical results.

The guest points to patient enrollment and patient selection as a more immediate win for AI, since a large share of phase two and phase three halts come from trial recruitment problems. But the guest is skeptical that AI alone can compress long clinical trials enough to transform timelines, noting that even an Alzheimer's prevention trial lasting three and a half years cannot be reduced to three weeks.